Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 3/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.44 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.42 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23760882 | 0.99 | NT5E (0.45) | NT5EP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL23760923 | 0.93 | NT5E (0.47) | NT5EP2RY1P2RY11RNASEL | |
| SCHEMBL23760903 | 0.88 | NT5E (0.47) | NT5EP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL24081826 | 0.88 | NT5E (0.48) | NT5EP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL23760748 | 0.87 | POLB (0.39) | NT5EP2RY1P2RX1P2RX3ENPP1 | |
| SCHEMBL23760890 | 0.85 | CA5A (0.42) | NT5EP2RY1P2RX3P2RY11RNASEL | |
| SCHEMBL23760891 | 0.85 | CA5A (0.42) | NT5EP2RY1P2RX3P2RY11RNASEL | |
| SCHEMBL23761055 | 0.84 | CYP2C19 (0.39) | NT5E | |
| SCHEMBL23760876 | 0.83 | POLB (0.53) | NT5EGPR17 | |
| SCHEMBL21136126 | 0.83 | NT5E (0.64) | NT5EP2RY1P2RX1P2RX3ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3865136-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR CORONA VIRUS TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |